Skip to main content
SpringerLink
Log in

c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

c-erbB2 is a proto-oncogene that encodes the trans- membrane protein p185. This protein shares considerable sequence and structure homology with members of the epidermal growth factor receptor family and it is believed to cooperate with these receptors in the signal transduction process in order to control cell proliferation. Overexpression of c-erbB2, with or without gene amplification, is frequently found in breast cancer, and a body of evidence suggests it is implicated in the development of resistance to the anti-estrogen tamoxifen. Scientific evidence strongly supports a correlation between c-erbB2 overexpression and lack of efficacy of tamoxifen in both advanced and adjuvant settings. However, given the important therapeutic repercussion of this topic, further studies are required before c- erbB2 evaluation can be routinely used to select patients who are likely to benefit from tamoxifen administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shih C, Padhy LC, Murray M, Weinberg RA: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290:261-264, 1981

    Google Scholar 

  2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139, 1985

    Google Scholar 

  3. Beerli RR, Hynes NE: Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 271:6071-6076, 1996

    Google Scholar 

  4. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all Erb B receptors, is a mediator of lateral signaling. EMBO J 16:1647-1655, 1997

    Google Scholar 

  5. Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE: Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 15:6496-6505, 1995

    Google Scholar 

  6. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y: ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254-264, 1996

    Google Scholar 

  7. Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, Di Fiore PP: The normal erbB2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol 2:992-1003, 1990

    Google Scholar 

  8. Borg A: Gene aberration in human breast cancer. Academic Dissertation. Lund, Wallin e Dalholm Boktryckeri AB, 1992

  9. Prigent SA, Lemoine NR: The type I (EGFR-related) family of growth factor receptors and their ligands. Progr Growth Factor Res 4:1-24, 1992

    Google Scholar 

  10. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987

    Google Scholar 

  11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989

    Google Scholar 

  12. Ravdin PM, Chamness GC: The c-erbB2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers. A review. Gene 159:19-27, 1995

    Google Scholar 

  13. Harris J, Lippman M, Veronesi U, Willett W: Breast cancer (3). N Engl J Med 327:473-480, 1992

    Google Scholar 

  14. Kuiper GGJM, Brinkmann AO: Steroid hormone receptor phosphorylation: is there a physiologic role? Mol Cell Endocrinol 100:103-107, 1994

    Google Scholar 

  15. Reddy KD, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK: Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res 52:3636-3641, 1992

    Google Scholar 

  16. Read LD, Keith D, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947-3951, 1990

    Google Scholar 

  17. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkoski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446, 1995

    Google Scholar 

  18. Liu Y, El-Ashry D, Chen D, Ding IYF, Kern FG: MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and a reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117, 1995

    Google Scholar 

  19. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard M, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1992

    Google Scholar 

  20. Vignon F, Bouton MM, Rochefort H: Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 146:1502-1508, 1987

    Google Scholar 

  21. Nicholson S, Wright C, Sainsbury RC, Halcrow P, Kelly P, Angus B, Farndon JR, Harris A: Epidermal growth factor receptor as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Molec Biol 37:811-814, 1990

    Google Scholar 

  22. Klijn JGM, Berns EMJJ, Bontenbal M, Foekens J: Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Revs 19:45-63, 1993

    Google Scholar 

  23. Berns EMJJ, Foekens JA, van Staveren IL, van Putten WLJ, de Koning HYWCM, Portengen H, Klijn JGM: Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159:11-18, 1995

    Google Scholar 

  24. Wright C, Nicholson S, Angus B, Sainsbury JRC, Farndon J, Cairns J, Harris AL, Horne CHW: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65:118-121, 1992

    Google Scholar 

  25. Elledge RM, Green S, Ciocca D, Pugh R, Allred C, Clark GM, Hill J, Ravdin P, O'Sullivan J, Martino S, Osborne CK: HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res 4:7-12, 1998

    Google Scholar 

  26. Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hösch S, Hayes DF: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15:2518-2525, 1997

    Google Scholar 

  27. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995

    Google Scholar 

  28. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Letters 81:137-144, 1994

    Google Scholar 

  29. Têtu B, Brisson J: Prognostic significance of the pattern of immunostaining and adjuvant therapy. Cancer 73:2358-2365, 1994

    Google Scholar 

  30. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 16:462-469, 1998

    Google Scholar 

  31. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S: c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early breast cancer without axillary lymph node metastases. J Clin Oncol 14:2702-2708, 1996

    Google Scholar 

  32. Bianco AR, De Placido S, Gallo C, Pagliarulo C, Marinelli A, Petrella G, D'Istria M, Delrio G: Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. Lancet ii:1095-1099, 1988

    Google Scholar 

  33. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 71–85, 1992

    Google Scholar 

  34. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467, 1998

    Google Scholar 

  35. Piantadosi S: Estimating Clinical Effects in Clinical Trials: A Methodological Perspective. Wiley-Interscience Publications, New York, 1997

    Google Scholar 

  36. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of intravenous recombinant human anti-p185 HER 2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996

    Google Scholar 

  37. Cobleigh MA, Vogel CL, Tripathy D, Robert NG, Scholl S, Fehrenbacher L, Paton V, Shak S, Lieberman G, Slamon D: Efficacy and safety of Herceptin (humanized anti-HER2·antibody) as a single agent in 22 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. J Clin Oncol: 97a, #376, 1998

    Google Scholar 

  38. Parker MG: Action of pure antiestrogen in inhibiting estrogen receptor action. Breast Cancer Res Treat 32:131-137, 1993

    Google Scholar 

Download references

Authors
  1. Sabino De Placido
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chiara Carlomagno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michelino De Laurentiis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Angelo Raffaele Bianco
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Placido, S., Carlomagno, C., De Laurentiis, M. et al. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res Treat 52, 55–64 (1998). https://doi.org/10.1023/A:1006159001039

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006159001039

Search

Navigation